Claims for Patent: 5,677,282

Summary for Patent: 5,677,282

Title:	Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
Abstract:	Amino acid amides of 5-amino-1,3,4-thiadiazole-2-thione are disclosed. These compounds inhibit matrix metalloproteinase enzymes and cartilage degradation. Methods of treating diseases caused by over-activity of matrix metalloproteinases, such as osteoarthritis and rheumatoid arthritis, are also disclosed.
Inventor(s):	Oleksyszyn; Jozef (Arlington, MA), Jacobson; Alan R. (Somerville, MA)
Assignee:	Proscript, Inc. (Cambridge, MA)
Application Number:	08/473,143
Patent Claims:	1. A compound represented by the following structural formula: ##STR3## wherein: Q and A are each independently selected from the group consisting of sulfur and oxygen and at least one of Q and A is sulfur; n is a positive integer which results in a matrix metalloproteinase inhibitor; R1 is selected from the group consisting of --H, lower alkyl and acyl; each R2 is independently selected from the group consisting of C.sub.1 -C.sub.10 straight or branched alkyl, C.sub.1 -C.sub.10 straight or branched substituted alkyl, C.sub.3 -C.sub.8 cyclic alkyl, substituted C.sub.3 -C.sub.8 cyclic alkyl, C.sub.1 -C.sub.10 straight or branched alkenyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, C.sub.1 -C.sub.10 straight or branched alkynyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl; R3 is selected from the group consisting of an amine protecting group X--CO--, X--CS--, X--S.sub.2 --, X--O--CO-- and X--O--CS--; X is selected from the group consisting of C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or a physiologically active salt thereof. 2. The compound of claim 1, wherein: n is an integer from 1-10; R1 is --H; and R3 is selected from the group consisting of X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO-- and X--O--CS--. 3. The compound of claim 2, wherein; A and Q are each sulfur; and each R2 is selected from the group consisting of a side chain of a naturally occurring amino acid, (substituted phenyl)-CH.sub.2 --, napthyl-CH.sub.2 --, (O-substituted)tyrosyl, cycloalkyl, (O-substituted)glutamoyl, (S-substituted)cysteinyl, (O-substituted) seryl, (N-substituted)glutamyl, (N,N-disubstituted)glutamyl, (N-.epsilon.-substituted)lysyl, aryl and substituted aryl. 4. The compound of claim 3, wherein: n is an integer from 1-4; and R3 is benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, (4-phenyl)phenylacetyl, 8-quinolinesulfonyl, 2-methylthionicotyl, xanthene-9-carbonyl, hydrocinamoyl, phenylbenzoyl, nonanoyl, (4-benzyloxy)benzoyl, acetyl and (4-(4-t-butylphenylsulfonamino)benzoyl. 5. The compound of claim 4, wherein: R2 is selected from the group consisting of phenyl, cylcohexyl and the side chain of (O-benzyl)tyrosine, (O-methylene-2-naphtyl)tyrosyl, (N-trityl)glutamyl, (N,N-dibenzyl)glutamyl, (N-2-phenylethyl)glutamyl, phenylalanine, valine and tryptophan; and R3 is selected from the group consisting of 4-phenylbenzoyl, nonanoyl, benzyloxybenzoyl and (4-(4-t-butylphenylsulfonamino)benzoyl. 6. The compound of claim 5, wherein the compound is 5-(N-(4-(4-t-butylphenylsulfonamino)benzoyl)-phenylalanyl-valylamino)-1,3, 4-thiadiazole-2-thione, 5-(N-benzyloxycarbonyl-(O-benzyl)tyrolsyl-phenylglycylamino)-1,3,4-thiadia zole-2-thione and N-(N-benzyloxycabonyl)-((N,N-dibenzyl)glutamyl)-phenylglycyamino)-1,3,4-th iadiazole-2-thione. 7. A method of inhibiting a matrix metalloproteinase, comprising contacting the matrix metalloproteinase with an inhibitory amount of a compound represented by the following structural formula: ##STR4## wherein: Q and A are each independently selected from the group consisting of sulfur and oxygen and at least one of Q and A is sulfur; n is a positive integer which results in a matrix metalloproteinase inhibitor; R1 is selected from the group consisting of --H, lower alkyl and acyl; each R2 is independently selected from the group consisting of C.sub.1 -C.sub.10 straight or branched alkyl, C.sub.1 -C.sub.10 straight or branched substituted alkyl, C.sub.3 -C.sub.8 cyclic alkyl, substituted C.sub.3 -C.sub.8 cyclic alkyl, C.sub.1 -C.sub.10 straight or branched alkenyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, C.sub.1 -C.sub.10 straight or branched alkynyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl; R3 is selected from the group consisting of an amine protecting group X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO-- and X--O--CS--; X is selected from the group consisting of C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or a physiologically active salt thereof. 8. The method of claim 7, wherein: Q and A are each sulfur; n is an integer from 1-10; R1 is --H; R3 is selected from the group consisting of X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO-- and X--O--CS--. 9. The method of claim 8, wherein: n is an integer from 1-4; each R2 is selected from the group consisting of a side chain of a naturally occurring amino acid, (substituted phenyl)-CH.sub.2 --, napthyl-CH.sub.2 --, (O-substituted)tyrosyl, cycloalkyl, (O-substituted)glutamoyl, (S-substituted)cysteinyl, (O-substituted) seryl, (N-substituted)glutamyl, (N,N-disubstituted) glutamyl, (N-.epsilon.-substituted)lysyl, aryl and substituted aryl; and R3 is benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, (4-phenyl)phenylacetyl, 8-quinolinesulfonyl, 2-methylthionicotyl, xanthene-9-carbonyl, hydrocinamoyl, phenylbenzoyl, nonanoyl, (4-benzyloxy)benzoyl, acetyl and (4-(4-t-butylphenylsulfonamino)benzoyl. 10. The method of claim 9, wherein the matrix metalloproteinase is selected from the group consisting of interstitial collagenase, stromelysin, gelatinases and human neutrophil collagenase. 11. A method for treating an individual with a disease, wherein said disease is ameliorated by inhibiting at least one matrix metalloproteinase enzyme, comprising administering a therapeutically effective amount of a compound represented by the following structural formula: ##STR5## wherein: Q and A are each independently selected from the group consisting of sulfur and oxygen and at least one of Q and A is sulfur; n is a positive integer which results in a matrix metalloproteinase inhibitor; R1 is selected from the group consisting of --H, lower alkyl and acyl; each R2 is independently selected from the group consisting of C.sub.1 -C.sub.10 straight or branched alkyl, C.sub.1 -C.sub.10 straight or branched substituted alkyl, C.sub.3 -C.sub.8 cyclic alkyl, substituted C.sub.3 -C.sub.8 cyclic alkyl, C.sub.1 -C.sub.10 straight or branched alkenyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, straight or branched alkynyl, C.sub.1 -C.sub.10 straight or branched substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl; R3 is selected from the group consisting of an amine protecting group X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO-- and X--O--CS--; X is selected from the group consisting of C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or a physiologically active salt thereof. 12. The method of claim 11, wherein the disease is osteoarthritis. 13. The method of claim 11, wherein the disease is rheumatoid arthritis. 14. The method of claim 11, wherein the disease is cancer. 15. The method of claim 11, wherein the inhibition of at least one matrix metlloproteinase enzyme results in a decrease in inflammation caused by the disease. 16. The method of claim 12, wherein: n is an integer from 1-10; R1 is --H; R3 is selected from the group consisting of X--CO--, X--CS--, X--SO.sub.2 --, X--O--CO-- and X--O--CS--. 17. The method of claim 16, wherein: n is an integer from 1-4; each R2 is selected from the group consisting of a side chain of a naturally occurring amino acid, (substituted phenyl)-CH.sub.2 --, napthyl-CH.sub.2 --, (O-substituted) tyrosyl, cycloalkyl, (O-substituted)glutamoyl, (S-substituted)cysteinyl, (O-substituted) seryl, (N-substituted)glutamyl, (N,N-disubstituted)glutamyl, (N-.epsilon.-substituted) lysyl, aryl and substituted aryl; and R3 is benzyloxycarbonyl, 9-fluoerenylmethoxycarbonyl, t-butoxycarbonyl, (4-phenyl)phenylacetyl, 8-quinolinesulfonyl, 2-methylthionicotyl, xanthene-9-carbonyl, hydrocinamoyl, phenylbenzoyl, nonanoyl, (4-benzyloxy)benzoyl, acetyl and (4-(4-t-butylphenylsulfonamino)benzoyl.

Details for Patent 5,677,282

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26